Arax Advisory Partners
INMB icon

Arax Advisory Partners’s INmune Bio INMB Stock Holding History

Arax Advisory Partners’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7K Buy
14,567
+14,501
+21,971% +$20.1K ﹤0.01% 3837
2026
Q1 		$75 Buy
+66
New +$94 ﹤0.01% 3633
2025
Q4 		– Sell
-490
Closed -$1.02K – 4300
2025
Q3 		$1.02K Buy
+490
New +$1.12K ﹤0.01% 3254

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arax Advisory Partners's INMB Position: Q2 2026 in Review

Arax Advisory Partners increased its INmune Bio (INMB) stake by 21,971% in Q2 2026, buying an estimated $20.1K and bringing the position to 14,567 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3837.

Arax Advisory Partners first reported a position in INMB in Q3 2025 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Arax Advisory Partners held 14,567 shares of INmune Bio worth $23.7K as of Q2 2026.
  • Arax Advisory Partners bought 14,501 INmune Bio shares in Q2 2026, an estimated $20.1K.
  • INmune Bio made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3837 holding.
  • Arax Advisory Partners first reported a position in INmune Bio in Q3 2025 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.